Okay, let’s give it a try, but keep in mind the majority of Americans with Rx insurance using co-pays and coinsurance and generic drugs will have little use for such a program. Estimates are that over 90% of Americans have some Rx coverage (99% for those on Medicare).
Any value will only come if the most expensive drugs are included. And of course, the process for getting the script through the website and willingness and ability to use mail order will be challenging.
The fact the website is to be named TrumpRx.com should tell you something about the personality of our President. More form than substance.
Oh yeah, Obamacare – that was not his idea, in fact it was intended as derogatory.
Trump’s strategy is pure coercion – effective in the short run, but not sustainable. 🤨
TrumpRx is the name of a new federal website and initiative announced by President Donald Trump as part of his administration’s push to lower prescription drug costs through a “most-favored-nation” pricing model.
Here are the known details:
- Website: The platform, referred to as TrumpRx.gov, is expected to launch in early 2026. It is designed to be a direct-to-consumer platform where individuals can search for and be directed to drug manufacturers’ online platforms to purchase medications at discounted rates, bypassing traditional middlemen.
- Most-Favored-Nation (MFN) Pricing: The initiative is tied to the MFN pricing policy, which aims to bring U.S. drug prices in line with the lowest prices paid for the same drugs in other developed nations.
- Pfizer Deal: The program was unveiled alongside an agreement with pharmaceutical giant Pfizer. Pfizer became the first major drugmaker to commit to the MFN policy, agreeing to:
- Offer prescription drugs to the Medicaid program at reduced MFN prices.
- Sell many of its drugs directly to consumers through the TrumpRx site at a significant discount, reportedly averaging around 50%.
- Ensure all new drugs it introduces in the U.S. market will follow the MFN pricing model.
- Tariffs: The deal with Pfizer also includes a commitment from the company to invest $70 billion in U.S. manufacturing and R&D in exchange for a three-year grace period from new tariffs the administration plans to impose on imported branded or patented pharmaceutical products.
Knowing all the details will be enlightening as will the overall impact when Pfizer is not alone in the process and there is competition.
QUINNSCOMMENTARY 